(Q39488926)

12 September 2017

title

IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-α. (English)

1 reference

12 September 2017

1 reference

1 reference

11

1 reference

12 September 2017

Jacinta A Holmes

1

1 reference

12 September 2017

Tin Nguyen

2

1 reference

12 September 2017

Dilip Ratnam

3

1 reference

12 September 2017

Neel M Heerasing

4

1 reference

12 September 2017

Jane V Tehan

5

1 reference

12 September 2017

Sara Bonanzinga

6

1 reference

12 September 2017

Anouk Dev

7

1 reference

12 September 2017

Sally Bell

8

1 reference

12 September 2017

Stephen Pianko

9

1 reference

12 September 2017

Robert Chen

10

1 reference

12 September 2017

Rachel Hammond

12

1 reference

12 September 2017

David Iser

13

1 reference

12 September 2017

Ferry Rusli

14

1 reference

12 September 2017

William Sievert

15

1 reference

12 September 2017

Paul V Desmond

16

1 reference

12 September 2017

D Scott Bowden

17

1 reference

12 September 2017

Alexander J Thompson

18

1 reference

12 September 2017

language of work or name

1 reference

1 May 2013

1 reference

Journal of Gastroenterology and Hepatology

12 September 2017

published in

1 reference

12 September 2017

volume

28

1 reference

12 September 2017

issue

5

1 reference

12 September 2017

page(s)

861-866

1 reference

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

12 September 2017

cites work

1 reference

Hepatitis B virus. The major etiology of hepatocellular carcinoma

21 January 2018

1 reference

Hepatocellular carcinoma and hepatitis B virus

21 January 2018

1 reference

Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.

21 January 2018

1 reference

Lamivudine for patients with chronic hepatitis B and advanced liver disease

21 January 2018

1 reference

Randomised controlled trial of interferon alfa 2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response

21 January 2018

1 reference

Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa

21 January 2018

1 reference

Efficacy and tolerability of pegylated interferon-α-2a in chronic hepatitis B: A multicenter clinical experience

21 January 2018

1 reference

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

21 January 2018

1 reference

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

Genetic variation in IL28B and treatment outcome in HBeAg-positive and -negative chronic hepatitis B patients treated with Peg interferon alfa-2a and adefovir.

21 January 2018

1 reference

Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy

21 January 2018

1 reference

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

21 January 2018

1 reference

Prediction of the response to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment

21 January 2018

1 reference

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

21 January 2018

1 reference

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus.

21 January 2018

1 reference

A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians.

21 January 2018

1 reference

Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population

21 January 2018

1 reference

IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection

21 January 2018

1 reference

Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers

21 January 2018

1 reference

Lamivudine resistance in patients with chronic hepatitis B: role of clinical and virological factors

21 January 2018

1 reference

Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia

21 January 2018

1 reference

Chronic hepatitis B: recommendations for therapy based on the natural history of disease in Australian patients

21 January 2018

1 reference

Polymorphisms Near IL28B and Serologic Response to Peginterferon in HBeAg-Positive Patients With Chronic Hepatitis B

21 January 2018

1 reference

Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/JGH.12110

1 reference

release_ymat3orsarelhklcyqmuyef7sm

12 September 2017

Fatcat ID

0 references

1 reference